Status:
COMPLETED
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
Lead Sponsor:
CoMentis
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-80 years
Phase:
PHASE2
Brief Summary
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participant...
Detailed Description
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participant...
Eligibility Criteria
Inclusion
- probable Alzheimer
Exclusion
- others
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00414622
Start Date
November 1 2006
End Date
April 1 2007
Last Update
April 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Dept.
280 South San Francisco, California, United States